Tuesday, October 15, 2019 11:57:20 AM
Refs:
1 http://www.globenewswire.com/news-release/2019/10/15/1929577/0/en/Replimune-Provides-Update-on-RP1-Clinical-Development-Program-in-Cutaneous-Squamous-Cell-Carcinoma.html
2 (there are some graphical images) https://ir.replimune.com/static-files/92ceb475-65c1-4086-a461-d3087a568ffe
Recent REPL News
- Replimune to Present at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 • GlobeNewswire Inc. • 09/15/2024 01:45:00 PM
- Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024 • GlobeNewswire Inc. • 09/09/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:05:15 PM
- Stockholders Vote to Elect Madhavan Balachandran to Board of Directors • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024 • GlobeNewswire Inc. • 08/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:00:04 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/15/2024 04:15:12 AM
- Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma • GlobeNewswire Inc. • 08/13/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/08/2024 12:45:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 12:06:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:04:11 PM
- Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/08/2024 12:00:00 PM
- Replimune to Present at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 07/30/2024 08:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/19/2024 08:15:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/19/2024 08:15:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:36:13 PM
- Replimune Announces $100 Million Private Placement Financing • GlobeNewswire Inc. • 06/13/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 12:30:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/07/2024 08:51:06 PM
- Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 01:15:41 PM
- Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma • GlobeNewswire Inc. • 06/06/2024 11:00:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM